

# Epigenetic alterations in the predisposition to and progression of melanoma

Salgado, C.

#### Citation

Salgado, C. (2020, October 21). *Epigenetic alterations in the predisposition to and progression of melanoma*. Retrieved from https://hdl.handle.net/1887/137852

Version: Publisher's Version

License: License agreement concerning inclusion of doctoral thesis in the

Institutional Repository of the University of Leiden

Downloaded from: <a href="https://hdl.handle.net/1887/137852">https://hdl.handle.net/1887/137852</a>

Note: To cite this publication please use the final published version (if applicable).

### Cover Page



## Universiteit Leiden



The handle <a href="http://hdl.handle.net/1887/137852">http://hdl.handle.net/1887/137852</a> holds various files of this Leiden University dissertation.

Author: Salgado, C.

Title: Epigenetic alterations in the predisposition to and progression of melanoma

**Issue date**: 2020-10-21

### LIST OF PUBLICATIONS

Interplay between *TERT* promoter mutations and methylation culminates in chromatin accessibility and *TERT* expression.

Salgado C, Roelse C, Nell R, Gruis N, van Doorn R, van der Velden P.

PLoS One. 2020 Apr 8:15(4):e0231418

Genome-wide characterization of 5-hydroxymethylcytosine in melanoma reveals major differences with nevus.

Salgado C, Oosting J, Janssen B, Kumar R, Gruis N, van Doorn R.

Genes Chromosomes Cancer. 2020 Jun; 59(6):366-374.

Genome-wide analysis of constitutional DNA methylation in familial melanoma.

<u>Salgado C</u>, Gruis N, BIOS Consortium, Heijmans BT, Oosting J, van Doorn R. Clinical Epigenetics. 2020 Mar 6; 12(1):43.

A novel germline variant in the *DOT1L* gene co-segregating in a Dutch family with a history of melanoma.

<u>Salgado C</u>, Kwesi-Maliepaard EM, Jochemsen AG, Visser M, Harland M, van Leeuwen F, van Doorn R, Gruis N.

Melanoma Res. 2019 Dec;29(6):582-589.

pmTOR is a marker of aggressiveness in papillary thyroid carcinomas.

Tavares C, Coelho MJ, Melo M, da Rocha AG, Pestana A, Batista R, <u>Salgado C</u>, Eloy C, Ferreira L, Rios E, Sobrinho-Simões M, Soares P.

Surgery. 2016 Dec; 160(6):1582-1590.

Poorly differentiated and undifferentiated thyroid carcinomas.

Eloy C, Ferreira L, Salgado C, Soares P, Sobrinho-Simões M.

Turk Patoloji Derg. 2015; 31 Suppl 1:48-59.

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, <u>Salgado C</u>, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Máximo V, Sobrinho-Simões M, Soares P. J Clin Endocrinol Metab. 2014 May;99(5):E754-65.

LRP1B (low density lipoprotein receptor-related protein 1B).

Prazeres H, Salgado C, Duarte C, Soares P.

Atlas Genet Cytogenet Oncol Haematol. 2014; 18(2):93-101.

### **ABOUT THE AUTHOR**

Catarina Salgado was born in Porto, Portugal, on the 22nd of August 1989. In 2007 started her bachelor degree in Biology at University of Porto. In 2009-2010 her first internship was performed at Institute of Pathology and Immunology (Portugal) within a project related to familial amyloidotic polyneuropathy, a type of amyloidosis endemic of the north of Portugal. Afterwards, between 2010 and 2012 she followed a Master Degree in Molecular Oncology granted by University of Porto and Portuguese Institute of Oncology and developed the master's project on familial thyroid carcinoma entitled "Exome-Sequencing of a familial thyroid cancer: genetic and functional characterization" under supervision of Dr. Hugo Prazeres and Prof. Paula Soares, Alongside she also contributed to other oncobiology research projects in Soares lab, which led to her first scientific publications (Atlas Genet Cytogenet Oncol Haematol, 2014; J Clin Endocrinol Metab, 2014; Turk Patoloji Derg, 2015; Surgery, 2016) and the Everis Award 2015. In August 2015, she was accepted as a PhD fellow, supported by the prestigious Innovative Training Network grant program by the European Union and integrated in the MELGEN network, at the Leiden University Medical Center (The Netherlands) to where she moved in January 2016. Since then, under supervision of Dr. Remco van Doorn and Dr. Nelleke Gruis, she established several collaborations with specialists from different fields (genomics, cell biology, bioinformatics and medical oncologists), supervised a master student (Celine Roelse) and co-supervised a bachelor student (Casper Wenzel) and orally presented her research at several national and international scientific conferences. All different aims of the PhD project resulted in firstauthor publications in peer-review journals (Melanoma Res, 2019; Genes Chromosomes Cancer, 2020; Clin Epigenetics, 2020; PLoS One, 2020). She participated as a Board Member in the LUMC Association for PhD candidates (2017-2019) as well as a scientist member of two international organizations developing outreach activities for children (Native Scientist and Letters to a Pre-Scientist).

### **ACKNOWLEDGEMENTS**

First of all, I would like to acknowledge the opportunity to pursue my PhD at the dermatology department of the Leiden University Medical Center (LUMC). Therefore, my gratitude goes to my supervisors and co-promotors Dr. Remco van Doorn, Dr. Nelleke Gruis and promotor Prof. Dr. Maarten Vermeer for guiding me throughout these four years full of scientific achievements in collaboration with top researchers in the field. I would also like to thank Bart Janssen as a co-supervisor for hosting me at GenomeScan for the completion of my secondment.

I am grateful to Prof. Dr. Julia Newton-Bishop, Prof. Dr. Tim Bishop and Dr. Juliette Randerson-Moor for considering me as a part of MELGEN network. Being part of a group of 16 unknown PhD fellows from all over the world who have become true companions has been very gratifying. I would like to thank Rita, Eirini, Adriana, Rohit, Shamik and Joey for all the support and the beautiful friendships we have built, full of cheerful moments. Moreover, I would like to thank the funding body, the Marie Skłodowska-Curie Early Training Network (ETN) by the European Union for sponsoring my project.

I would like to acknowledge the entire dermatology group at LUMC, both lab members and clinicians, for all the scientific discussions and technical assistance over the last years, in particular Wim Zoutman and Coby Out. A special thank you for my talented and hardworking Master student Celine Roelse.

I would also like to thank our collaborators from LUMC, namely AG Jochemsen (Department of Cell and Chemical Biology), Jan Oosting (Department of Pathology), Pieter van der Velden, Rogier Nell, Mieke Versluis (Department of Ophthalmology), Haico van Attikum, Wouter Wiegant, Jaap Jansen, Martijn Luijsterburg (Department of Human Genetics) and Els Verdegaal (Department of Medical Oncology) and from Netherlands Cancer Institute, Fred van Leeuwen and Eliza Mari Kwesi-Maliepaard, for all their invaluable contributions to this work.

Às minhas amigas queridas, obrigada pela profunda amizade, por poder contar sempre com o vosso apoio pessoal e profissional, pelos convívios por esse mundo fora, sempre emotivos e divertidos.

À minha família que são o meu verdadeiro alicerce, agradeço o apoio incondicional e o orgulho infinito em mim – somos 1, os 5. À minha Avó pela referência que sempre foi e por me ter ensinado o que é a emancipação e independência. Ao Ricardo, pelo tanto que significou nesta caminhada. Que o Amor e o respeito continuem a fazer parte de todos os capítulos da nossa história. Desta forma, o longe fez-se perto.